Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118530 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Zhihao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Antibodies, Bispecific, Immunoconjugates. Die Arbeit nennt 141 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In recent years, monoclonal antibodies (mAbs) have become a new type of drug for disease treatment. Especially, the bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR)-T cell therapies, all derived from targeting properties of mAbs, have achieved great success in the field of tumor treatment. However, due to the low expression of tumor-associated antigens in normal tissues, the "on-target, off-tumor" toxicity produced by these therapies has limited their development. To solve this problem, researchers have designed protease-activated, low pH-sensing, and high extracellular ATP-responsive pro-antibodies leveraging the special biochemical conditions of the tumor microenvironment (TME). This review summarizes the mechanism of action, recent advances, and the limitations of different TME-responsive pro-antibodies. Given the relative maturity of the protease-activated platform, its applications have been extended to bispecific antibodies, ADCs, and CAR-T cell therapies, which are also summarized in this review. Finally, we discuss the problems faced in the clinical translation of TME-responsive pro-antibodies, including low production yield and the lack of suitable preclinical animal models for safety assessment. In summary, this review provides a new perspective on the development of safe and efficient next-generation antibody therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China.
- School of International Education, Zhengzhou University, Zhengzhou 450001, China.
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhe…
- Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China; Henan Provincial Engineering Research Center for Cancer Chemoprevention, Zhengzhou 450001, China; Henan Pro…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z., Zhang, M., Li, Y., Jahromi, A. S., Liu, K., Zhao, J., & Li, G. (2026). Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118530
Vancouver
Wang Z, Zhang M, Li Y, Jahromi AS, Liu K, Zhao J, et al. Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118530
BibTeX
@article{Wang2026,
author = {Wang, Zhihao and Zhang, Mengjia and Li, Yanchen and Jahromi, Ali Sahraianali and Liu, Kangdong and Zhao, Jimin and Li, Guoming},
title = {Recent advances in tumor microenvironment-responsive pro-antibody to overcome on-target, off-tumor toxicity},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118530}
}
EUVIMED